PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A child's family income and the neighborhood they grow up in may play a much bigger role in brain development than previously believed, according to a new study published in Science. Researchers at Washington University in the United States analyzed brain scans from nearly 12,000 children aged 9 to...
A new Canadian study has found that social anxiety disorder (SAD) affects nearly one in seven adults, making it one of the country's most common mental health conditions. The findings, published in Psychiatry Research, showed that the number of people experiencing social anxiety has increased by 71%...
A new review suggests that music therapy may offer meaningful benefits for people living with neurological, psychiatric, and chronic health conditions, but its wider adoption in clinical practice continues to be limited by workforce shortages, inconsistent standards, and gaps in research.
BioCryst Pharmmaceuticals Inc. (BCRX), a biotechnology company, on Friday released new data from the real-world APeX-P study for ORLADEYO and the Phase 1b/2 ALPHA-STAR for Navenibart in treating hereditary angioedema. ORLADEYO (berotralstat) is an oral prophylactic therapy that increases plasma kallikrein...